Biohaven Ltd. (BHVN)
BHVNNYSEBiotechnology: Pharmaceutical Preparations
$13.80
-0.2900 (-2.06%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $2.09bn
- P/E
- –
- EPS, last 4 quarters
- $-3.86
- Dividend yield
- –
- Day range
- –
- 52-week range
- $7.78 to $18.24
- Average volume
- –
- Previous close
- $14.09
Analysts
13 coveringBuy8 buy, 4 hold, 1 sell
Targets a year out average $25.00, +81.2% from here
Earnings
next estimate $-0.3500Next report
Dec 2025
+0.8%
Mar 2026
-2.3%
Jun 2026
-18.2%
Sep 2026
-7.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$142.73m | -$130.43m | -$124.90m | -$126.42m |
| Net income | -$145.56m | -$130.53m | -$137.31m | -$129.28m |
News
8 latest- Biohaven Consensus Price Target Increased 10.16% to $24.48Fintel · Nov 2, 2026
- Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to TradeZacks · Oct 29, 2026
- Biohaven's BHV-1420 Targets PLA2R Autoantibodies In Membranous Nephropathy RTTNews · Oct 26, 2026
- March 2027 Options Now Available For Biohaven (BHVN)BNK Invest · Oct 23, 2026
- Biotech Stocks Rally: BHVN Jumps 31%, KRRO Climbs 25%, ATNM And VCRE Gain RTTNews · Oct 22, 2026
- Biohaven's Troriluzole NDA Accepted For FDA Review; Decision In Q1 2027; Stock Up RTTNews · Oct 22, 2026
- Biohaven Licenses IgG Degrader Portfolio To Ono Pharma In Key Asian Markets RTTNews · Oct 8, 2026
- Weekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal RTTNews · Aug 28, 2026
The company
Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across immunology, neuroscience, and oncology. Biohaven is advancing an innovative portfolio of therapeutics built on proven drug development experience and multiple proprietary platforms, including Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; next generation ADC platform for oncology; and myostatin inhibition for neuromuscular and metabolic diseases, including obesity.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- Region
- North America
- Website
- biohaven.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.